1. Home
  2. PLUR

as of 03-12-2026 9:31am EST

$3.31
+$0.08
+2.32%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Founded: 2001 Country:
Israel
Israel
Employees: N/A City: HAIFA
Market Cap: 33.9M IPO Year: 2001
Target Price: $12.00 AVG Volume (30 days): 6.3K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.36 EPS Growth: 10.78
52 Week Low/High: $2.82 - $7.13 Next Earning Date: N/A
Revenue: $1,336,000 Revenue Growth: 309.82%
Revenue Growth (this year): 97.38% Revenue Growth (next year): 293.97%
P/E Ratio: -2.38 Index: N/A
Free Cash Flow: -19829000.0 FCF Growth: N/A

Share on Social Networks: